Insight Molecular Diagnostics (IMDX) Gross Margin (2020 - 2026)
Insight Molecular Diagnostics (IMDX) posted Gross Margin of 46.88% for Q1 2026, up 7.64% sequentially from 43.55% in Q4 2025, and down 1510.0% YoY from 3.32% in Q1 2025.
Insight Molecular Diagnostics (IMDX) Gross Margin (2020 - 2026) Analysis & Trends
Insight Molecular Diagnostics has reported Gross Margin for 7 years, with the latest figure at 46.88% in Q1 2026.
- Quarterly Gross Margin fell 1510.0% year-over-year to 46.88% in Q1 2026, while the trailing twelve-month figure through Mar 2026 was 51.31% (down 125.0% YoY) and the FY2025 annual result came in at 56.67%, up 1733.0% from the prior year.
- Gross Margin climbed to 46.88% in Q1 2026 per IMDX's latest filing, from 43.55% in the prior quarter.
- Over five years, Gross Margin peaked at 67.57% in Q2 2025 and troughed at 401.49% in Q3 2022.
- A 5-year average of 8.7% and a median of 43.48% in 2024 frame the typical range for Gross Margin.
- The sharpest annual moves came in 2022 and 2023: Gross Margin slumped 31348 bps in 2022, then surged 45930 bps in 2023.
- Over 5 years, Gross Margin stood at 0.68% in 2022, then slumped by 5405 bps to 37.26% in 2023, then jumped by 207 bps to 40.04% in 2024, then climbed by 9 bps to 43.55% in 2025, then grew by 8 bps to 46.88% in 2026.
- According to Business Quant data, Gross Margin over the past three periods registered 46.88%, 43.55%, and 53.46% for Q1 2026, Q4 2025, and Q3 2025 respectively.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Gross Margin (Qtr) |
|---|---|---|---|---|---|
| 1 | Thermo Fisher Scientific | 213.88 Bn | 209.81 Bn | 8.34 Bn | 69.57% |
| 2 | Danaher | 140.65 Bn | 136.30 Bn | 3.61 Bn | 57.64% |
| 3 | Idexx Laboratories | 46.02 Bn | 45.83 Bn | 779.09 Mn | 64.04% |
| 4 | Agilent Technologies | 39.85 Bn | 38.05 Bn | 990.00 Mn | 53.95% |
| 5 | Iqvia Holdings | 39.20 Bn | 37.12 Bn | 1.44 Bn | 32.85% |
| 6 | Natera | 38.80 Bn | 37.70 Bn | 696.04 Mn | 99.91% |
| 7 | Illumina | 30.11 Bn | 28.94 Bn | 770.00 Mn | 66.44% |
| 8 | Mettler Toledo International | 28.66 Bn | 28.61 Bn | 650.22 Mn | 63.29% |
| 9 | Quest Diagnostics | 26.24 Bn | 25.61 Bn | 1.03 Bn | 33.75% |
| 10 | Insight Molecular Diagnostics | 172.42 Mn | 143.49 Mn | 15,000.00 | 46.88% |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2026 | 46.88% |
| Dec 31, 2025 | 43.55% |
| Sep 30, 2025 | 53.46% |
| Jun 30, 2025 | 67.57% |
| Mar 31, 2025 | 61.97% |
| Dec 31, 2024 | 40.04% |
| Sep 30, 2024 | 43.48% |
| Jun 30, 2024 | 48.08% |
| Mar 31, 2024 | 25.57% |
| Dec 31, 2023 | -37.26% |
| Sep 30, 2023 | 57.81% |
| Jun 30, 2023 | 58.75% |
| Mar 31, 2023 | 3.37% |
| Dec 31, 2022 | -0.68% |
| Sep 30, 2022 | -401.49% |
| Jun 30, 2022 | 13.08% |
| Mar 31, 2022 | 23.66% |
| Dec 31, 2021 | 72.47% |
| Sep 30, 2021 | -88.01% |
| Jun 30, 2021 | -19.41% |